Anxiety-like behaviour is attenuated by gabapentin, morphine and diazepam in a rodent model of HIV anti-retroviral-associated neuropathic pain

Neuropathic pain is commonly associated with affective disorders such as anxiety and depression. We have previously characterised a rodent model of HIV, anti-retroviral-associated neuropathy in which rats develop hypersensitivity to a punctate mechanical stimulus and display anxiety-like behaviour in the open field paradigm. To assess the potential of this behavioural paradigm for the assessment of pain related co-morbidities in rodent models of pain, here we test the sensitivity of this anxiety-like behaviour to the analgesic agents gabapentin and morphine in comparison to the known anxiolytic drug diazepam. We found that gabapentin (30 mg/kg, i.p.) and morphine (2.5 mg/kg, i.p.), which reduce mechanical hypersensitivity in these rats, significantly reduces measures of thigmotaxis in the open field. The effect of gabapentin and morphine did not differ significantly from diazepam (1 mg/kg, i.p.). This study highlights the potential use of this rodent model and behavioural paradigm in the validation of the affective component of novel analgesic pharmacological targets and elucidation of underlying pathophysiological mechanisms.

[1]  E. Rüther,et al.  Pharmacological validation of a chronic social stress model of depression in rats: effects of reboxetine, haloperidol and diazepam , 2008, Behavioural pharmacology.

[2]  J. Breuer,et al.  Further characterization of a rat model of varicella zoster virus–associated pain: Relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs , 2007, Neuroscience.

[3]  J. Desmeules,et al.  Differential action of morphine and various opioid agonists on thermal allodynia and hyperalgesia in mononeuropathic rats , 1994, Pain.

[4]  Ronald Dubner,et al.  A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury , 1990, Pain.

[5]  J. Quinn,et al.  Behavioural changes in the rat following infection with varicella-zoster virus. , 1999, The Journal of general virology.

[6]  A. Holmes,et al.  Mechanical and cold hypersensitivity in nerve-injured C57BL/6J mice is not associated with fear-avoidance- and depression-related behaviour. , 2007, British journal of anaesthesia.

[7]  Salahadin Abdi,et al.  The Anti-Allodynic Effects of Amitriptyline, Gabapentin, and Lidocaine in a Rat Model of Neuropathic Pain , 1998, Anesthesia and analgesia.

[8]  Jin Mo Chung,et al.  An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat , 1992, PAIN.

[9]  K. Ä. Möller,et al.  Assessing mechanical allodynia in the rat paw with a new electronic algometer , 1998, Journal of Neuroscience Methods.

[10]  H. Anderson,et al.  Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking drugs , 2005, Pain.

[11]  M. Maschke,et al.  A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies , 2004, Journal of Neurology.

[12]  C. Woolf,et al.  Spared nerve injury: an animal model of persistent peripheral neuropathic pain , 2000, Pain.

[13]  J. Ochoa,et al.  NEUROPATHIC PAIN: REDEFINITION AND A GRADING SYSTEM FOR CLINICAL AND RESEARCH PURPOSES , 2009, Neurology.

[14]  Andrew R Segerdahl,et al.  Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain. , 2007, Brain : a journal of neurology.

[15]  J. Herman,et al.  Limbic and HPA axis function in an animal model of chronic neuropathic pain , 2006, Physiology & Behavior.

[16]  T. Nurmikko,et al.  Analgesic Therapy in Postherpetic Neuralgia: A Quantitative Systematic Review , 2005, PLoS medicine.

[17]  Andrew S.C. Rice,et al.  Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy , 2007, PAIN®.

[18]  M. Bourin Animal models of anxiety: are they suitable for predicting drug action in humans? , 1997, Polish journal of pharmacology.

[19]  J. de Vry,et al.  Pharmacological characterization of the chronic constriction injury model of neuropathic pain. , 2004, European journal of pharmacology.

[20]  A. Dickenson,et al.  Gabapentin Normalizes Spinal Neuronal Responses That Correlate with Behavior in a Rat Model of Cancer-induced Bone Pain , 2005, Anesthesiology.

[21]  M. Backonja,et al.  The effect of continuous morphine analgesia on chronic thermal hyperalgesia due to sciatic constriction injury in rats , 1995, Neuroscience Letters.

[22]  Rolf-Detlef Treede,et al.  Anxiety-like behaviour in rats with mononeuropathy is reduced by the analgesic drugs morphine and gabapentin , 2008, PAIN.

[23]  John F. Cryan,et al.  Model organisms: The ascent of mouse: advances in modelling human depression and anxiety , 2005, Nature Reviews Drug Discovery.

[24]  R. J. Leo Chronic pain and comorbid depression , 2005, Current treatment options in neurology.

[25]  Klaus-Peter Lesch,et al.  Mice Lacking the Serotonin Transporter Exhibit 5-HT1A Receptor-Mediated Abnormalities in Tests for Anxiety-like Behavior , 2003, Neuropsychopharmacology.

[26]  J. Farrar,et al.  Core outcome measures for chronic pain clinical trials: IMMPACT recommendations , 2003, Pain.

[27]  N. B. Finnerupa,et al.  Algorithm for neuropathic pain treatment: An evidence based proposal , 2005 .

[28]  M. Zimmermann,et al.  Ethical guidelines for investigations of experimental pain in conscious animals , 1983, Pain.

[29]  J. Turner,et al.  Chronic pain and depression: does the evidence support a relationship? , 1985, Psychological bulletin.

[30]  R. Gallagher,et al.  The psychopharmacologic treatment of depression and anxiety in the context of chronic pain , 2002, Current pain and headache reports.

[31]  S. Verma,et al.  Comorbidities in chronic neuropathic pain. , 2004, Pain medicine.

[32]  R. Gallagher,et al.  Managing pain and comorbid depression: A public health challenge. , 1999, Seminars in clinical neuropsychiatry.

[33]  D. Cottrell,et al.  Focal Lysolecithin-Induced Demyelination of Peripheral Afferents Results in Neuropathic Pain Behavior That Is Attenuated by Cannabinoids , 2003, The Journal of Neuroscience.

[34]  A. Rice,et al.  Comparison of psychological and physical function in neuropathic pain and nociceptive pain: Implications for cognitive behavioral pain management programs , 2008, European journal of pain.

[35]  H. J. McQuay,et al.  Algorithm for neuropathic pain treatment: An evidence based proposal , 2005, Pain.

[36]  T. Gordh,et al.  Peripheral neuropathic pain—a multidimensional burden for patients , 2001, European journal of pain.

[37]  Tomoe Takagi,et al.  Usefulness of Antidepressants for Improving the Neuropathic Pain-Like State and Pain-Induced Anxiety through Actions at Different Brain Sites , 2008, Neuropsychopharmacology.

[38]  A. Rice,et al.  The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L‐29) on pain behaviour in rodent models of neuropathy , 2007, British journal of pharmacology.

[39]  J. Levine,et al.  Novel mechanism of enhanced nociception in a model of AIDS therapy-induced painful peripheral neuropathy in the rat , 2004, Pain.

[40]  Blair H. Smith,et al.  Health and Quality of Life Associated With Chronic Pain of Predominantly Neuropathic Origin in the Community , 2007, The Clinical journal of pain.